Annual
Report
2006 (Business & Finance Report)
Interactive
version of the entire Annual Report 2006
 | Business
Report | Finance Report |
Annual
Media Conference
IR
Conference
& Presentations to Investors
 Letter
from the
Chairman
Dear Shareholders
2006 was another year
of strong growth and outstanding financial performance at Roche.The Group’s sales rose 17% in local
currencies to a record high of 42 billion Swiss francs.This 6.5 billion Swissfranc revenue increase
over 2005 reflects organic growth.Top-line growth was driven primarily by the Pharmaceuticals Division,
where sales advanced at more than three times the market growth rate in 2006. Roche Diagnostics maintained
its leadership position in an increasingly competitive market, thanks to numerous new product launches
and continued growth in all of the division’s business areas. ...more ...
 Roche
Group: Group results - Outlook - Group strategy
Operationally and
financially, 2006 was another outstanding year for the Roche Group. Total sales increased significantly,
rising 17% in local currencies (18% in Swiss francs) to 42.0 billion Swiss francs. This 6.5 billion
Swiss franc increase over 2005 revenues was all organic growth. Sales continued to grow especially strongly
in the Pharmaceuticals Division. Its sales increased 21% for the year in local currencies (22% in Swiss
francs), or more than three times the global market growth rate, led by strong demand for the cancer
medicines Herceptin, Avastin and MabThera/Rituxan, the anti-influenza medicine Tamiflu, and Bonviva/Boniva,
for osteoporosis. As a result, Roche extended its market leadership in oncology, transplantation and
virology. In the Diagnostics Division sales increased 5% in local currencies (6% in Swiss francs) to
8.7 billion Swiss francs, with the Centralized Diagnostics unit making the largest contribution to growth.
Diagnostics sales accelerated during 2006 and grew slightly ahead of the market for the year as a whole.
... more ...
|
 |
print this page